Life Science Investing Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Life Science Investing Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia
Life Science Investing Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia
TomaGold Intercepts 6.68% ZnEq (1.57 g/t AuEq) over 48.05 Metres, including 39.03% ZnEq (9.15 g/t AuEq) over 2.90 Metres at Berrigan Mine and Identifies a Major Hydrothermal Footprint
Surface Metals Inc. Sells Remaining Interest in Manitoba Lithium Project to Earn-in Partner Snow Lake Energy
